Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arena Lays Out Path Forward For Lorcaserin

This article was originally published in The Pink Sheet Daily

Executive Summary

Arena Pharmaceuticals and Japanese partner Eisai plan to resubmit an NDA for the controversial obesity drug lorcaserin by the end of 2011.

You may also be interested in...

Positive Panel Recommendation For Contrave Could Change Obesity Drug Game

FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.

Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin

The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.

FDA Issues Complete Response Letter for Arena's Lorcaserin

Concerrns Raised by Advisory Committee Come Back to Haunt Lorcaserin, the company's first product to go through regulatory process.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts